Abstract: Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.
Introduction
Gastric and gastro-oesophageal cancer represent a significant global health burden. In 2012 there were just fewer than 1.5 million new cases and 1.1 million deaths from gastro-oesophageal cancer worldwide, making gastric cancer (GC) the third leading cause of cancer death in both men and women. The prevalence of gastro-oesophageal cancer varies widely with geography, with more than 70% of cases occurring in the developing world, the highest incidence being found in Eastern Asia, mainly in China [Ferlay et al. 2014] .
Whilst in recent decades there has been a decline in the overall incidence of GC worldwide, the proportion of tumours of the gastric cardia, consisting of the proximal stomach and the gastrooesophageal junction (GOJ), has increased. This is thought to be due to a combination of factors, including eradication treatment for Helicobacter pylori and improving diet and sanitation reducing the number of noncardia tumours, and the increase in obesity-associated gastro-oesophageal reflux disease leading to a rise in Barrett's oesophagus and a subsequent increase in the number of cardia tumours [Shah and Kelsen, 2010] .
Over the last 40 years, the 5-year relative survival rates for GC have tripled, but the actual survival rate remains low, with less than one in five patients surviving for more than 5 years. For advanced disease the prognosis is particularly bleak, with a median overall survival (OS) of only 3 months with best supportive care, and approximately 12 months with first-line combination chemotherapy.
Current standard of care
The first-line standard of care for metastatic or inoperable locally advanced gastro-oesophageal cancer consists of a doublet of a platinum and a fluoropyrimidine, or a triplet with the addition of epirubicin or a taxane. In 2010 the practice changing ToGA trial led to the addition of trastuzumab to the standard doublet for those patients who are Human Epidermal Growth Factor Receptor 2 (HER2) positive, approximately 20% of patients with advanced gastro-oesophageal cancer [Bang et al. 2010] . The addition of trastuzumab in this study resulted in a median OS of 16 months for the subgroup of HER2-positive patients with HER2 3+ on immunohistochemistry (IHC) testing or HER2 2+ on IHC with positive HER2 on fluorescence in situ hybridization testing. As yet, however, there is no standard targeted first-line treatment for HER2-negative patients.
There is less international consensus regarding second-line treatment, but irinotecan, docetaxel and weekly paclitaxel are all used in this situation Thuss-Patience et al. 2011; Ford et al. 2014; Hironaka et al. 2013] . Across the studies performed in this setting the OS with best supportive care has ranged from 2.4 to 3.8 months, whereas the OS with single-agent chemotherapy has been between 4 and 9.5 months. However, it must be noted that the upper limit of survival quoted here is from the Japanese study of paclitaxel versus irinotecan where approximately 80% of patients went on to have third-line chemotherapy. In the other studies, OS was between 4 and 5.3 months (Figure 1 ). This benefit with second-line chemotherapy was further supported by a meta-analysis conducted in 2013 of over 400 patients treated with secondline docetaxel or irinotecan, in which a significant reduction in the risk of death was observed with salvage chemotherapy [hazard ratio (HR) 0.64, 95% confidence interval (CI) 0.52-0.79; p < 0.0001] [Kim et al. 2013] .
However, this benefit associated with second-line cytotoxic treatment is short lived, highlighting the need for improved treatment in this setting. Furthermore, for patients with progressive disease following first-line treatment for advanced gastro-oesophageal cancer, quality of life and maintaining performance status are key therapeutic goals and the toxicity of chemotherapy must not be overlooked. In these studies of second-line or subsequent chemotherapy, treatment toxicity was significant, particularly gastrointestinal symptoms, which are known to adversely impact quality of life [Al-Batran et al. 2015] (Table 1) .
Targeted therapies
In recent years, the elucidation of various molecular pathways involved in the development of GC has led to a multitude of studies of targeted therapies. There is, as yet, no single clear molecular driver for gastro-oesophageal cancer, but following the success of the ToGA trial discussed above, agents targeting the vascular endothelial growth factor (VEGF) angiogenesis pathway, the hepatocyte growth factor pathway (MET), the phosphoinositide 3 kinase inhibitor/mammalian target of rapamycin (PI3K/mTOR) pathway and other agents targeting the epidermal growth factor receptor family (EGFR) have all been investigated (Table 2) .
So far, these trials of targeted agents have been disappointing, with only trastuzumab in the firstline setting and ramucirumab in the second-line setting demonstrating a significant survival benefit. This may be, in part, due to the lack of predictive biomarkers for the majority of agents, with trastuzumab being a notable exception. In addition, the heterogeneity in molecular alterations seen in gastro-oesophageal cancer worldwide, add further complexity to the results from these large multi-centre studies.
A number of recent publications have clearly demonstrated that there is a range of distinct subsets of GC and gastro-oesophageal cancers according to genomic alterations [Deng et al. 2012; Bass et al. 2014] . Such research may allow patients to be stratified in future trials of targeted agents, until better predictive biomarkers are elucidated. Previously treated advanced GC/GOJC
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Targeting angiogenesis and ramucirumab
ImClone Systems (New York) developed ramucirumab as a fully humanized monoclonal antibody, directed against VEGFR2. The compound was initially isolated from a naïve human antibody phage display library. A subsequent in vitro selection process, using an additional specific phage display library, selected a high affinity variant for further development [Lu et al. 2003 ]. This variant, clone 1121B, ramucirumab, binds to domain 3, close to the N terminus, and inhibits VEGF-induced signalling by altering the conformation of the receptor, preventing VEGF binding [Franklin et al. 2011] . By specifically binding VEGF2, ramucirumab prevents all known VEGFs binding to VEGF2 and therefore could lead to more complete inhibition of angiogenesis than agents directly binding a single VEGF.
Early studies
Ramucirumab has been extensively investigated in the preclinical setting, with murine studies demonstrating proof of principle [Prewett et al. 1999] . In vitro data have shown that ramucirumab has an 8-9-fold stronger affinity for VEGFR2 than the nascent ligand VEGFA [Lu et al. 2003] and binds VEGFR2 with an IC50 (half maximal inhibitory concentration) of 1-2 nM [Miao et al. 2006] .
Three phase I studies with ramucirumab have been completed [ClinicalTrials.gov identifier: NCT00793975, NCT00786383 and NCT01005355], although only one of these has been published [Spratlin et al. 2010 ]. This study recruited 37 patients with a range of advanced solid malignancies, including four with GC or oesophageal cancer, and treated them with escalating doses of once-weekly ramucirumab, between 2 and 16 mg/kg. Following dose-limiting toxicities of hypertension and deep vein thrombosis, the maximum tolerated weekly dose was set at 13 mg/kg. Other toxicities seen were nausea, vomiting, headache, fatigue and proteinuria.
Fifteen percent (4 of 27) of the patients with measurable disease had a partial response (PR) and the disease control rate (PR + stable disease) was 73% for all patients (27 of 37). Furthermore, 30% (11 of 37) of all patients had either a PR or stable disease lasting for 6 months or longer. Based on this tolerable safety profile and signal of anticancer activity, further phase II and III studies of ramucirumab were undertaken. There has only been one phase II study in gastro-oesophageal cancer, which followed on from the large phase III second-line studies discussed below.
Advanced studies

Efficacy data for second-line treatment
The two large phase III studies of ramucirumab in gastro-oesophageal cancer have been in the second-line setting. The first of these was the REGARD study, an international, randomized, multicentre, placebo-controlled trial of ramucirumab monotherapy conducted between 2009 and 2012 [Fuchs et al. 2014] .
A total of 355 patients with advanced GC or GOJ cancer were randomized (2:1) to best supportive care plus ramucirumab 8 mg/kg intravenously or placebo 2 weekly, following disease progression on first-line chemotherapy. There was no crossover at progression and the primary endpoint was OS.
The treatment arms were well balanced, with over 75% of patients having gastric tumours, 70% of patients having a performance status of 1 and 69% of patients being recruited from Western populations (Europe, North America and the Antipodes).
Response rates were only 4% with ramucirumab treatment, but the rate of stable disease was considerably higher than in the placebo arm (45% versus 21%), resulting in a significantly greater disease control rate of 45% versus 23%. However, the median duration of treatment was only 8 weeks [interquartile range (IQR) 6-16] in the ramucirumab arm and 6 weeks (IQR 4-8) in the placebo arm.
Median OS was increased in the ramucirumab arm to 5.2 months compared with 3.8 months in the placebo arm (HR 0.776, 95% CI 0.603-0.998, p = 0.047). This benefit remained significant after multivariable adjustment for prognostic factors such as performance status, presence of peritoneal disease and site of primary disease. This is the first randomized trial to demonstrate such a survival advantage for a single-agent antiangiogenic monoclonal antibody in a solid tumour. Progressionfree survival (PFS) at 6 months was also improved to 42% with ramucirumab versus 32% with placebo. These results are comparable with those seen using standard second-line chemotherapy in this setting, with less toxicity.
Based on these results the FDA granted ramucirumab a priority review and subsequently approved it for the treatment of GC and GOJ cancer on 14 April 2014.
The RAINBOW study recruited 665 patients with advanced GC or GOJ adenocarcinoma between December 2010 and September 2012 [Wilke et al. 2014] . They were randomized to treatment with either paclitaxel and ramucirumab or paclitaxel and placebo, following disease progression on or within 4 months of first-line chemotherapy. The study was double blind and multicentre, involving 27 countries, with a primary endpoint of OS.
Baseline characteristics between the two treatment groups were generally well balanced. Approximately two-thirds of the patients had progressive disease on first-line chemotherapy, 80% of patients had a gastric primary, roughly 60% of patients had performance status of 1 and 60% were from Europe, Israel, Australia and America, with 33% from Asia and 7% from South America.
OS was significantly longer in the paclitaxel plus ramucirumab arm (9.6 months, 95% CI 8.5-10.8 months, versus 7.4 months, 95% CI 6.3-8.4 months; HR 0.807, 95% CI 0.678-0.962, p = 0.017) and median PFS was improved to 4.4 months versus 2.9 months with placebo with a stratified HR of 0.635 (95% CI 0.536-0.752, p < 0.0001). Ramucirumab also improved the objective response rate (28% versus 16% with placebo) and achieved a disease control rate of 80% versus 64% with placebo.
The survival data in RAINBOW were analysed according to geographic region, comparing Asian and non-Asian patients. The OS benefit was not significant for Asian patients, although PFS remained significantly improved. The HRs for survival were 0.73 and 0.99 for non-Asian and Asian patients respectively for OS, and 0.64 and 0.63 for non-Asian and Asian patients for PFS. It was suggested that this difference could be explained by the higher use of third-line therapy following study discontinuation in Asian patients compared with nonAsian patients (almost 70% versus almost 40%).
A subsequent efficacy analysis was carried out contrasting Japanese and Western (European, American and Australian) patients in RAINBOW and found that in the Japanese population a benefit was seen in PFS, ORR (overall response rate) and OS at 6 months. Again post discontinuation therapy rates were much higher in the Japanese patients at 75% than in the Western patients at 37% and it was postulated that this masked the potential OS benefit .
Based on the data from the RAINBOW study in September 2014, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion for the use of ramucirumab, in combination with paclitaxel, or as a single agent if combination is not appropriate, for the treatment of advanced GC or GOJ adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. The FDA also extended the license for ramucirumab in November 2014 to include its use in combination with paclitaxel in the treatment of GC and GOJ adenocarcinoma, following failure of first-line treatment.
Toxicity data for second-line treatment
In REGARD adverse event rates were similar between the two treatment arms, other than hypertension, which was significantly higher in the ramucirumab arm at 16% versus 8%, as would be expected. Rates of bleeding and haemorrhage, venous thromboembolic events, fistula formation and perforation, in particular, were similar in both arms. There were more arterial thromboembolic events in the ramucirumab arm (2% versus 0%) but only four patients were affected across all grades.
Quality of life data were collected in REGARD but the percentage of patients providing this at the first 6-week assessment was very low, due to treatment discontinuation. Of these patients, a larger number in the ramucirumab group reported stable or improved global quality of life, but this was not significant. Time to deterioration in performance status to 2 or worse was also measured and was significantly better in the ramucirumab group at 5.1 months (IQR 1.9-16.8) versus 2.4 months (IQR 1.3-not reached) in the placebo group (HR 0.586, 95% CI 0.414-0.829, p = 0.002).
In the RAINBOW study grade 3 adverse events were seen in 47% of patients in the ramucirumab arm and 39% of patients in the placebo arm. Hypertension (35% versus 6%), proteinuria (17% versus 6%), bleeding (mainly low-grade epistaxis) or haemorrhage (43% versus 18%) and gastrointestinal perforations (four patients, including one death, versus one patient) were more commonly seen in the ramucirumab plus paclitaxel arm, as expected with antiangiogenic treatment. Grade 3 or 4 neutropenia, leucopoenia, abdominal pain, fatigue and neuropathy (associated with a higher cumulative paclitaxel dose) were also all more common in the ramucirumab plus paclitaxel arm. Febrile neutropenia was similar in both groups (3% versus 2%). However, importantly, the higher frequency of grade 3 and 4 adverse events in the ramucirumab plus paclitaxel arm did not result in more patients discontinuing treatment or in a higher number of treatment-related deaths (2% in each group).
Quality of life data were also collected here, with no impairment of global quality of life from QLQ-C30 (EORTC questionnaire) or index scores from EQ-5D-3L (health outcome instrument) with the addition of ramucirumab to paclitaxel. Furthermore, quality of life was maintained for longer, with more patients reporting stable or improved scores with ramucirumab [Al-Batran et al. 2014] . Deterioration in performance status was measured again but here the HR of 0.798 was not significant (95% CI 0.612-1.040, p = 0.0941).
Based on these two large phase III studies, ramucirumab therefore has a favourable side-effect profile compared with cytotoxic drugs. Specifically the addition of ramucirumab to paclitaxel did not increase the incidence of side effects in a clinically meaningful fashion. In these studies ramucirumab treatment helped to maintain quality of life and as a single agent prolonged the time to deterioration of performance status, both important therapeutic goals.
Advanced studies
First-line treatment
In a recent randomized, double-blind, placebocontrolled phase II study, ramucirumab was used first line in combination with FOLFOX in advanced GC or oesophageal adenocarcinoma [Yoon et al. 2014] . A total of 168 patients were enrolled across 47 sites in America to receive FOLFOX (5FU, folinic acid, oxaliplatin) plus ramucirumab (8 mg/kg intravenously) or placebo, 2 weekly.
The study did not meet the primary endpoint of improved median PFS, with a PFS of 6.4 months in the ramucirumab arm and 6.7 months in the placebo arm (HR 0.98, 95% CI 0.69-1.37, p = 0.89). The PFS rate was higher at 3 months in the ramucirumab arm (89% versus 75%, p = 0.02), but not at any other time point. OS was 11.7 months in the ramucirumab arm and 11.5 months in the placebo arm. Response rate was not improved by ramucirumab (45% versus 46%), although disease control rate (made up of stable disease, complete response and PR) was higher in the ramucirumab arm (85% versus 67%, p = 0.008).
Approximately 50% of the patients in the study had oesophageal cancer and 50% had GC/GOJ cancer, well distributed between the treatment groups. Overall the patients with GC and GOJ cancer appeared to derive more benefit from the ramucirumab. In the GC/GOJ cancer subgroup analysis, OS was 14.6 months in the ramucirumab arm and 12.5 months in the placebo arm. In exploratory analyses, when PFS was censored at treatment discontinuation for nonprogressive disease, HR for PFS favoured the ramucirumab arm (PFS 9.3 months versus 7.6 months; HR 0.53, 95% CI 0.29-0.97, p = 0.036).
The treatment was fairly well tolerated with the expected grade 3 adverse events of neutropenia, fatigue, neuropathy and hypertension. However, treatment discontinuation for nonprogressive disease was more common in the ramucirumab arm and although both groups received a similar number of oxaliplatin cycles (8.5 versus 9.5), patients in the ramucirumab arm received fewer cycles of 5-fluorouracil (5FU) (9 versus 11) and ramucirumab/placebo (9 versus 11). The investigators suggested that this higher discontinuation rate and lower drug exposure might have impacted upon the PFS assessment.
It is difficult to establish why a differential effect was seen with ramucirumab treatment and oesophageal cancer versus GC and GOJ cancer. There could be intrinsic biological differences in how the tumour types respond to antiangiogenic treatment, or in the importance of completing 5FU treatment, but this could also simply be a chance finding from a subgroup analysis.
Discussion and future
A treatment milestone
Without doubt the improvement in OS with single agent ramucirumab in the REGARD study represents an important milestone in antiangiogenic treatment, as the first single agent antiangiogenic antibody to demonstrate a survival advantage in a solid tumour. Moreover, ramucirumab is the first targeted agent to improve survival, as a single agent or in combination, in a molecularly unselected population with GC and GOJ cancer.
Treatment is generally well tolerated, with the toxicities expected for an antiangiogenic agent. Although these toxicities cannot be described as trivial, it should be noted that the number of treatment-related deaths were low and in the RAINBOW study, treatment-related deaths were equal in both the treatment and placebo groups, at only 2%.
As with the majority of studies, the patients selected in RAINBOW and REGARD were younger and fitter than some patients with second-line GC or gastro-oesophageal cancer may be and whether toxicity in the real world becomes more of an issue remains to be seen. However, in these trials, quality of life was not impaired and in fact the addition of ramucirumab maintained a stable or improved quality of life for longer than placebo. A potential chemotherapy-free option in patients in this setting, who may have residual toxicity from chemotherapy or simply be fed up with chemotherapy, is a very welcome addition to the treatments available, especially when maintaining quality of life is of utmost importance.
Geographical variability
In contrast to the AVAGAST study of bevacizumab in combination with first line chemotherapy in gastric and gastro-oesophageal cancer [Ohtsu et al. 2011] , the REGARD study showed a similar survival benefit in Asian and non-Asian patients. In AVAGAST a survival benefit and improved response rate were only seen on subset analysis in the non-Asian patients. Even in RAINBOW where OS was not improved in Asian patients, response rate and PFS were. It is possible that disease biology varies across the globe such that geographical region may act as a surrogate marker for sensitivity to a particular antiangiogenic agent. The mechanistic advantage of ramucirumab, binding VEGF2 and its long half life, may also better bevacizumab. Interestingly the recent phase III study of apatinib, an oral small molecule VEGFR2 TKI, in advanced GC in Chinese patients demonstrated a prolonged median OS in the apatinib arm of 195 days versus 140 days in the placebo arm (HR 0.71, 95% CI 0.54-0.94, p < 0.0001) [Qin, 2014] . Finally, the success of antiangiogenic therapy may also vary in the first-and second-line setting, as supported by the first-line study of ramucirumab in combination with FOLFOX failing to meet its primary endpoint.
Biomarkers
For ramucirumab, alongside other antiangiogenic agents, or indeed targeted treatments generally, the lack of predictive biomarkers in patients with GC is frustrating. Biomarkerdriven patient selection may have changed the outcome of the first-line phase II study of ramucirumab in combination with FOLFOX.
There are as yet limited data on potential biomarkers for GC and GOJ cancer. In the AVAGAST study high levels of circulating VEGFA and increased neuropilin 1 expression were associated with worse survival in the placebo arm and benefit from bevacizumab in the treatment arm [Van Cutsem et al. 2012] . Of particular note, the effect associated with circulating VEGFA levels was only seen in patients from non-Asian-Pacific regions. Asian patients tended to have lower overall VEGFA levels, but even those with higher levels did not benefit from bevacizumab treatment. These results were potentially biased by geographic variations in tissue acquisition and processing and are as such hypothesis generating. The translational work from the RAINBOW and REGARD studies will hopefully add to this body of work and may yield new potential predictive biomarkers to enable better patient selection for antiangiogenic treatment.
If such a biomarker is developed, ramucirumab could be trialled in the perioperative, adjuvant or even maintenance setting. Rational drug combinations, perhaps with other antiangiogenic agents to overcome possible resistance mechanisms, could also be very interesting.
Further trials are already planned in gastrooesophageal cancer, combining ramucirumab with capecitabine and cisplatin in the first-line setting (RAINFALL) [ClincalTrials.gov identifier: NCT02314117], combining ramucirumab with nab-paclitaxel in the second-line setting [ClincalTrials.gov identifier: NCT02317991] and studying different doses and schedules as a single agent in the second-line setting.
At present, although ramucirumab has been approved by the FDA and has been granted orphan designation by the European Commission, there have been questions raised over its cost effectiveness. With an appropriate predictive biomarker to enable better patient selection it would be easier to answer such concerns.
It is to be hoped that with the increasing accessibility of high throughput techniques and the large blood and tissue banks from these sizeable multinational studies that progress in the development of a predictive biomarker for ramucirumab treatment will be made in the near future, which could significantly widen the potential use of this drug.
